GlassScriptPhysician profile
Anthony J Papadopoulos
NPI 1801852678
$8,516.06
in general payments reported to CMS, 2019-2025
31 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $654 · 2021: $1,205 · 2022: $1,277 · 2023: $1,350 · 2024: $1,344 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,283.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,030.29 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $948.46 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Sun Pharmaceutical Industries INC. | $822.47 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $790.77 | 2022-2025 | |
| Leo Pharma INC. | $688.12 | 2019-2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $656.42 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Regeneron Healthcare Solutions, INC. | $520.95 | 2019-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $429.08 | 2019-2025 | |
| Genzyme Corporation | $413.01 | 2019-2025 | |
| Pfizer INC. | $317.78 | 2019-2023 | |
| Epi Health, LLC | $275.47 | 2019-2022 | |
| Incyte Corporation | $251.79 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $247.10 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $230.97 | 2019-2025 | |
| Dermavant Sciences, INC. | $197.00 | 2023-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $146.67 | 2019-2025 | Klisyri |
| Organon LLC | $101.56 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $66.91 | 2019-2020 | |
| Lilly USA, LLC | $66.73 | 2021-2022 | |
| Medimetriks Pharmaceuticals, INC. | $56.83 | 2024 | |
| Celgene Corporation | $52.30 | 2019 | |
| Botanix Sb INC | $51.62 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $40.47 | 2022 | |
| Encore Dermatology INC. | $26.03 | 2019 | |
| Ucb, INC. | $16.72 | 2025 | Bimzelx |
| Dermira, INC. | $14.86 | 2019 | |
| Janssen Biotech, INC. | $13.79 | 2025 | Tremfya |
| Taro Pharmaceuticals USA, INC. | $13.22 | 2019 | |
| Sebela Pharmaceuticals INC. | $12.97 | 2020 | |
| Vyne Pharmaceuticals INC. | $12.85 | 2021 | |
| Prugen, INC. Pharmaceuticals | $2.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Papadopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.